Also mention amount of anticoagulant and activator calcium chloride to be used
PRP platelet rich plasma preparation anticoagulant sodium citrate calcium chloride activator amounts protocol
anticoagulant amount sodium citrate calcium chloride activator PRP preparation
calcium chloride concentration volume ratio to activate PRP platelet rich plasma
PRP preparation sodium citrate 3.2% 1:9 ratio blood collection calcium chloride 10% 50ul per ml activation protocol
| Anticoagulant | Concentration | Ratio to Blood | Notes |
|---|---|---|---|
| Trisodium Citrate (most common) | 3.2% or 3.8% | 1:9 (1 part anticoagulant : 9 parts blood) | Standard for platelet studies; 3.2% preferred for PRP |
| ACD-A (Acid Citrate Dextrose) | Standard formulation | 1:6 to 1:9 (typically 1 mL ACD-A per 6 mL blood) | Considered superior — better platelet morphology, higher TGF-β1 and PDGF-BB concentrations |
| EDTA | — | — | Avoid — dissociates GPIIb/IIIa complex, damages platelet membrane |
| Heparin | — | — | Less preferred; can cause platelet aggregation artefacts |
Practical example: For a 27 mL blood draw (a common PRP protocol), use 3 mL of ACD-A or sodium citrate → yields ~3–5 mL of PRP after centrifugation.
| Parameter | Details |
|---|---|
| Concentration used | 10% CaCl₂ is most commonly cited in literature |
| Volume ratio | 50 µL (0.05 mL) of 10% CaCl₂ per 1 mL of PRP |
| Alternative concentrations | 2.5% CaCl₂ — associated with better cell proliferation and fibroblast adhesion; 5% CaCl₂ — intermediate effect; 10% CaCl₂ — rapid activation but may cause pain (low pH ~6.3) |
| Physiological protocol (Anitua) | Less anticoagulant (0.4 mL of 3.8% sodium citrate) + 20 µL/mL activator |
| Conventional protocol (Anitua) | More anticoagulant (0.9 mL of 3.8% sodium citrate) + 50 µL/mL activator |
| Activator | Dose | Characteristics |
|---|---|---|
| Bovine/autologous thrombin | 10% solution | Immediate growth factor release; risk of immune reaction with bovine thrombin |
| Calcium chloride + thrombin | Combined | Rapid + sustained GF release |
| Collagen type I | 10% | Sustained release; reduces overall GF concentration |
| No activation (endogenous) | — | Adequate for soft tissue injection (collagen in tissue acts as natural activator) |